Concizumab: A Breakthrough Prophylaxis for Hemophilia B and A with Inhibitors
The World Federation of Hemophilia (WFH) shared a breakthrough for hemophilia with inhibitors on X:
”While treatment options have advanced, people with hemophilia B and inhibitors still face major gaps. A new review explores concizumab, a subcutaneous prophylaxis option that could help close that gap and improve outcomes.”
Read the full article here.
Despite advancements in hemophilia treatment, people with hemophilia A or B (HA, HB) and inhibitors face significant unmet needs, particularly in prophylaxis.
While emicizumab addresses prophylaxis for HA with inhibitors, no such option existed for HB until the arrival of concizumab.
This novel, subcutaneous treatment—approved since 2023 in countries like Canada, Australia, Japan, and Switzerland—is the first prophylactic therapy for HB with inhibitors.
The drug also offers new hope for HA patients with persistent bleeds on emicizumab.
With a unique mechanism of action, convenient multi-dose pen delivery, and quick washout, concizumab is poised to improve quality of life and long-term outcomes in this historically underserved population.
Hemostasis Today, your daily update on the latest advancements in the field of Hemophilia.
-
Jul 14, 2025, 12:32Anticoagulation in Liver Transplant Candidates: Is Apixaban Safe?
-
Jul 14, 2025, 12:30The Heart: Managing Warfarin-Induced Coagulopathy - New Insights into Handling Prolonged INR Levels
-
Jul 14, 2025, 12:26Investing in the Future of Stroke Innovation: SVIN Pilot Grant Empowers Early-Stage Research in Vascular Neurology
-
Jul 14, 2025, 12:22NEJM Publishes BRIDGE-TNK Trial: IV Tenecteplase Before Thrombectomy in Acute Ischemic Stroke
-
Jul 13, 2025, 15:33ISTH Now Accepting Applications for SSC Leadership Roles
-
Jul 14, 2025, 18:253 Valuable Takeaways from the ANGEL-REBOOT Trial for ICAS-O Stroke
-
Jul 14, 2025, 16:12567-Patient Study Confirms LMWH Safety in Pregnancy
-
Jul 13, 2025, 18:182025 ASH ISTH NBDF WFH monitoring report Confirms Strength of 2021 VWD Diagnosis and Management Guidelines
-
Jul 13, 2025, 17:57Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
-
Jul 13, 2025, 17:172024 NHLBI Workshop Charts Promising Future Directions for ECMO-Induced Coagulopathy
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025